Leading Structural Biology Outsourcing Services

SARomics Biostructures is a leading structural biology services company that supports the entire lifecycle of drug discovery and fragment-based drug design projects. We utilize advanced technologies and provide FastLane drug target protein structures, as well as protein structure services through protein crystallography and NMR spectroscopy.

SARomics Biostructures is a leading provider of structural biology CRO services. The company was established in 2006 by scientists with extensive experience across structural biology and structure-based drug design. The company rapidly gained recognition across North America, South America, Asia, Europe, and Australia. A video presentation by Björn Walse, CEO of SARomics Biostructures, provides additional details on the company’s services. See also our articles on the advantages of outsourcing early drug discovery services and why clients entrust our company with their drug discovery and structural biology projects.

Below is a more detailed description of our integrated services.

MAX IV synchrotron radiation laboratory supports i wide range of structural biology projects

Our laboratories and offices are situated near the MAX IV synchrotron laboratory, a fourth-generation synchrotron in Lund. By combining a high-intensity beam with advanced automation, the protein X-ray crystallography beamlines at MAX IV support crystallographic fragment screening, serial crystallography, and room-temperature X-ray crystallography.

Celebrating 100 Years of Structural Biology and 20 Years of SARomics Biostructures!

On June 2, 1926, a manuscript by James B. Sumner (Department of Physiology and Biochemistry, Cornell University Medical College, Ithaca) titled “THE ISOLATION AND CRYSTALLIZATION OF THE ENZYME UREASE” was received for publication in J. Biol. Chem. In the introduction, the author writes, “I discovered on the 29th of April a means of obtaining from the jack bean a new protein which crystallizes beautifully and whose solutions possess to an extraordinary degree the ability to decompose urea into ammonium carbonate”. This was the first time protein crystals were described as “beautiful”, an expression so familiar to all protein crystallographers! At a time when proteins were thought to be a type of colloids, Sumner demonstrated for the first time that they possessed a defined and stable atomic structure and could crystallize. Additionally, he showed that enzymes were actually proteins.
Another remarkable publication of 1926 was by T. Svedberg and R. Fåhraeus, published in JACS with the title “A new method for the determination of the molecular weight of the proteins”, in which, for the first time, the molecular weight of hemoglobin was determined by analytical centrifugation to be 66 kDa.

Eight years later, in 1934, the first report of X-ray diffraction by a protein crystal was published. This was a Nature paper by J. D. Bernal and D. Crowfoot, titled “X-ray photographs of crystalline pepsin”. The authors mention that the protein was crystallized by Dr. Philpot in the Laboratory of Prof. The Svedberg in Uppsala and brought to Cambridge by Dr. G. Millikan. Still, the world had to wait 24 more years until the first protein structure was finally determined. After solving the phase problem, J. C. Kendrew et al., in 1958, reported the structure of myoglobin, and in 1960, M. F. Perutz et al. published the structure of hemoglobin. In 1962, they were awarded the Nobel Prize in Chemistry. This marked the beginning of a long chain of Nobel Prizes awarded for work in structural biology, the most recent in 2024 for the development of computational methods for protein structure prediction. The Nobel Committee stated, “David Baker has succeeded with the almost impossible feat of building entirely new kinds of proteins. Demis Hassabis and John Jumper have developed an AI model to solve a 50-year-old problem: predicting proteins’ complex structures”. Since the first protein crystals were obtained, structural biology has developed into an interdisciplinary field within modern biological sciences that employs a range of complementary biophysical techniques to examine biological structures and functional processes at the atomic level.

SARomics Biostructures entered the field of structural biology 80 years after the first publication describing urease crystallization. Starting with just one employee and a small crystallization room at the MAX II synchrotron, we developed a fully equipped technical platform for structural biology research, including protein cloning, expression, purification, characterization, and crystallization. Today, SARomics Biostructures offers a broad range of structural biology services, including protein structure determination using X-ray crystallography and NMR spectroscopy, fragment library screening with weak-affinity chromatography (WAC™), NMR spectroscopy, and crystallographic fragment screening. Over the past two decades, the team has worked with many drug-target classes, providing high-quality structural biology services to the biotech and pharmaceutical industries.

Below is a more detailed description of our services. Additional information about our experimental platform can be found in our technology platform overview and on our blog.

protein Structure Services: Custom X-ray Crystallography & NMR Spectroscopy

SARomics Biostructures’ structural biology technology platform offers high-throughput custom CRO protein structure services using X-ray crystallography and NMR spectroscopy. Our crystallography services rely on regular data collection at the 4th generation MAX IV synchrotron in Lund. Our location near the synchrotron provides considerable flexibility in beamline access and ensures reliable sample delivery to the beamlines.
Our services include:


Our state-of-the-art laboratories employ biophysical methods such as dynamic light scattering (DLS), differential scanning fluorimetry (DSF), and size-exclusion chromatography (SEC) for protein characterization before crystallization. To enhance the efficiency of our crystallization experiments, we employ high-throughput liquid-handling robotics and plate hotels maintained at different temperatures and monitored by an automated imaging system. Please view the details of project workflow.

Two experimental stations at MAX IV leverage our X-ray crystallography protein structure services: BioMax and the newly opened MicroMax. Furthermore, the MicroMax beamline is particularly well-suited for serial X-ray crystallography experiments.
For details, please get in touch with us.


Drug Discovery Services: Fragment Screening and Structure-Based Drug Design

Our integrated structural biology services platform will assist your lead discovery and structure-based drug design efforts. Our offers include fragment screening & fragment-based drug discovery, and structure-based lead optimization services. You will also get exclusive access to our proprietary fragment libraries and weak-affinity chromatography (WAC™) screening technology, jointly owned by SARomics Biostructures and RG Discovery.
Additionally, our leading fragment screening capabilities encompass:

Protein-ligand complex, an example of structure-based drug design

Biophysical fragment screening techniques such as NMR spectroscopy and crystallography help identify weak binders to proteins, characterize ligand binding sites and reveal the details of molecular interactions within the ligand-protein complexes. Our proprietary fragment library, optimized for weak-affinity chromatography and NMR screening, includes about 1,300 low-molecular-weight (<220) MedChem-friendly compounds. These compounds are designed to cover diverse chemical spaces and are general-purpose. More than 90% of the compounds are commercially available, enabling rapid SAR generation.
For crystallographic fragment screening, we have designed a specific kinase-focused fragment library in collaboration with the FragMax platform staff. The FragMax facility was explicitly designed to facilitate crystallographic fragment screening projects. Our blog post on this subject discusses the advantages of crystallographic fragment screening and details of the service.

Our clients are also welcome to send their own libraries for screening. Please get in touch with us to discuss the requirements.
We also invite you to explore our overview of strategies for structure-based drug design.

Recombinant Proteins For Drug Discovery

Highly purified crystallization-grade proteins are essential for any structural biology, protein structure and drug discovery services project. Our comprehensive catalog features high-purity drug-target recombinant proteins expressed and purified to the highest standards in our protein lab. These proteins have undergone rigorous characterization using biophysical methods and other methods.

high purity proteins

Why Choose SARomics Biostructures for Your Structural Biology Project?

Our services workflow enables us to deliver hundreds of protein X-ray and NMR structures annually for various early-stage drug discovery projects. Since our establishment in 2006, we have successfully solved thousands of protein structures and submitted more than 500 disclosable structures to the Protein Data Bank (PDB). We have also contributed to numerous publications in high-ranking journals, including seven papers in Nature between 2021 and 2024.

When you entrust your structural biology and drug discovery project to our company, you can expect:

  • Access to a unique proprietary method for compound screening
  • Support from highly experienced and dedicated professionals
  • A guaranteed high-quality service and a high level of satisfaction
  • Prompt responses to your inquiries and realistic project timelines
  • Project management by a company with a strong brand identity and a state-of-the-art technology platform

See also our blog posts on why clients entrust us with their drug discovery and structural biology projects and about the advantages of outsourcing early drug discovery to a CRO.

SARomics Biostructures Lab at Medicon Village

SARomics Biostructures laboratories and offices are located in the new modern laboratory building at Medicon Village, Lund. Medicon Village is Scandinavia’s largest research and development cluster of biotech companies, built to support innovation and collaborations in advanced research and business.

Our blog explores Protein Structure Determination, Experimental structural biology & drug discovery techniques and Applications.

It also includes the latest company updates, highlights new publications, and features our team’s contributions.

Antibody 3D structure image
3D Epitope Mapping Techniques

We discuss the advantages of 3D epitope mapping using X-ray crystallography and cryo-electron microscopy.

crystallographic fragment screening technique is one of the recent developments in experimental structural biology
Crystallographic Fragment Screening

Overview of crystallographic fragment screening, the most effective method for screening fragment libraries.

MAX IV synchrotron radiation laboratory
Synchrotron radiation in drug discovery

We discuss a study conducted by the AstraZeneca team on the impact of synchrotron radiation on drug discovery.